September 2017


In this Supplement

Drug-Eluting Technologies

Choosing the Best Option Through Data-Informed Decision Making




Download a PDF of this supplement

The State of Peripheral Drug‑Eluting Technologies

By Michael R. Jaff, DO

Interim Results From the Muenster Postmarket All-Comers Registry

A look at the latest data on use of the Eluvia drug-eluting stent in challenging SFA lesions.

By Theodosios Bisdas, MD, PhD

Twelve-Month Results From the RANGER-SFA Trial

What these findings tell us about the safety and efficacy of the Ranger drug-coated balloon.

With Dierk Scheinert, MD

Economic Analysis Supporting the Use of Drug-Eluting Technologies in the Femoropopliteal Artery

These evolving modern therapies are showing promise in reducing health care costs while offering better outcomes.

By Konstantinos Katsanos, MSc, MD, PhD, EBIR

Clinical Benefit of Long-Length Drug-Coated Balloons

The anatomic factors that make longer DCBs the ideal choice for treating longer, more difficult lesions.

By Gunnar Tepe, MD

Experience With Atherectomy and DCBs

The merits of a two-part approach in the SFA and popliteal artery.

By Ulrich Sunderdiek, MD, PhD

Experience With Drug-Eluting Technologies in BTK Interventions

Promising results for drug-eluting stent use in CLI patients with lesions below the knee.

By Hans van Overhagen, MD, PhD, EBIR

New Technologies to Solve the Challenges of CLI

The unique features of this disease are finally being addressed with new devices.

By J.A. Mustapha, MD, and Fadi Saab, MD

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.